Exenatide Audit ABCD Edinburgh Spring 2014 - Poster

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cull², KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶,J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² on behalf of the ABCD Nationwide exenatide^* and liraglutide^† audit contributors

¹School of Medicine and Pharmacology University of Western Australia, Perth, Australia

²Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

³St John’s Hospital, Livingston, UK

⁴Heatherwood and Wexham Park Hospitals NHS Foundation Trust, Wexham, UK

⁵Pennine Acute Hospitals NHS Trust, Greater Manchester, UK

⁶Victoria Hospital, Kirkcaldy, UK

⁷The Ulster Hospital, Dundonald, UK

⁸Hull Royal Infirmary, Hull, UK

^*The exenatide audit contributors are listed in reference 2
^†The liraglutide audit contributors are listed in reference 3